
FDA Fast Tracks INX-315 for Tough-to-Treat Ovarian Cancer
The Food and Drug Administration (FDA) granted fast track designation to treatment with INX-315, a novel, potent and selective CDK2 inhibitor, to treat CCNE1-amplified platinum-resistant/refractory ovarian cancer, according to a press release from …